The Motley Fool, founded in 1993 by brothers David and Tom Gardner, is a multimedia financial services company dedicated to empowering individual investors with accessible, actionable advice. Headquartered in Alexandria, Virginia, the company offers a range of products, including stock recommendations, investment research, and personal finance guidance, through its popular website, newsletters, podcasts, and premium subscription services.
The Best Tech ETF to Invest $2,000 in Right Now This ETF has tech companies leading the way with a built-in hedge.
2 Cathie Wood Stocks to Buy on the Dip See beyond the near-term headwinds and focus on the long-term upside.
Alphabet vs. Amazon: Which One Will Make You Richer? Both of these stocks look like exceptional AI-powered picks in 2026.
Could This Beaten-Down AI Stock Stage the Comeback of 2026? Samsara's stock had a rough go of things in 2025, despite the fact that the company is growing fast and operates in a fast-growing industry.
Is It Time to Buy This Historically Cheap E-Commerce Stock? (Hint: It's Not Amazon) Given that online shopping is a durable secular trend, it makes sense why investors want to allocate capital to this sector.
1 Top ETF I Plan to Load Up on This Month This ETF delivers a growing stream of dividend income.
Should You Buy Archer Aviation While It's Below $8? Archer's share price has soared over the past three years, but there are some significant red flags with this stock.
3 Easiest Ways to Boost Your Social Security Benefits For millions of Americans, Social Security benefits represent a financial lifeline. Here's how you can make the most of yours.
This AI Stock Could Be Your Best Shot at Life-Changing Gains A cheap valuation and stunning growth make this AI stock worth buying hand over fist before it soars higher.
2 No-Brainer Warren Buffett Stocks to Buy Right Now You can take a set-it-and-forget-it approach with these two industry leaders.
Is GameStop the Next Berkshire Hathaway? Since becoming CEO, Ryan Cohen has redefined GameStop's business and invested company funds outside of retailing.
Prediction Markets Are the Hot New Thing, but Will They Be a Good Long-Term Investment? Prediction markets offer a unique way to make money, even if top cryptocurrencies are in the red.
Here's Why You'll Probably Never Hit a 'Perfect' 850 Credit Score Achieving a perfect 850 credit score takes decades. But you can copy the same habits and still get top loan rates and credit cards.
Here's Why Pfizer Stock Is Still a Buy Pfizer has fallen behind the pack when it comes to GLP-1 drugs, but the company is still fighting.
4 Questions to Figure Out the Right Time to Claim Social Security You may not be able to predict exactly how long you'll live, but it's a good idea to plan for a longer-than-expected life.
One of Under Armour's 10% Owners Buys 2.6M Shares as Legal Setbacks Come to A Close A 10% owner of Under Armour purchased multiple shares of the company towards the end of January 2026. Is this a signal to purchas UA stock?
Could This Tech-Heavy Vanguard Fund Be Due for a Significant Decline in 2026? The Vanguard Information Technology ETF gives investors positions in leading tech companies, but it comes with risk.
Meta Platforms' $135 Billion Bet Makes Complete Sense The market keeps rewarding this business, as shares benefit from positive momentum.
3 Things to Know About Starlink Before the 2026 SpaceX IPO Don't invest in the SpaceX IPO until you understand the Starlink business.
Prediction: These Will Be the Best-Performing AI Stocks in 2026 All three of these AI stocks should have tremendous momentum this year.
Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's Stock Maze Therapeutics' Senior Vice President of Finance sold shares towards the end of January 2026, all while the company's stock had one of the best first-year performances of a biopharmaceutical company.
Wall Street Has a Federal Reserve Problem, With a Perfect Storm Brewing in 2026 Wall Street's foundational financial institution is rife with red flags, and the stock market could pay the price.
Beam Therapeutics Senior Vice President Sells 6,198 Shares for $216,933 Beam Therapeutics specializes in gene-editing medicines, and recently, the company's Senior Vice President edited out thousands of shares from her portfolio.
3 Vanguard ETFs to Buy to Protect Your Portfolio from a Potential Stock Market Crash These Vanguard funds won't necessarily keep you from losing money if the market crashes. But they can help cushion the blow.
Retirees on Social Security Just Got Some Good News From Uncle Sam Retirees' 2026 Social Security COLA might taste a little better after a recent government report.
3 Stocks That Turned $1,000 Into $1 Million (or More) In all three cases it started with a must-have product or service that's easy and affordable enough to buy over and over again.
Sandisk Stock Is Up 1,500% in the Past Year Due to AI -- Is It Still a Buy? Wall Street Has a Surprising Answer for Investors. Sandisk stock increased 16x in the past year as demand for artificial intelligence infrastructure led to a severe supply shortage in memory chips and storage devices.
The AI Stock Wall Street Insiders Are Quietly Buying Billionaires are buying this maker of critical mapping and positioning software at a discount.
CareDx's CEO Conducts Multiple Sale of Shares Towards the End of January 2026 The CEO of this leading medical diagnostic company sold shares throughout multiple days in January. But the manner in which the shares were sold shouldn't concern investors.
Could Royal Caribbean and Six Flags Be Lifelong Leisure Stocks for Your Portfolio? Leisure stocks can provide good returns, if you can ride out the waves during economic downturns.
Harmony Biosciences Chief Financial Officer Sells Shares Again After Previous Exit From Company Equity This top executive at Harmony Biosciences previous sold all of his direct shares in the company in early January 2026. But towards the end of the month, some options and restricted stock units vested, and everything changed.
Scholar Rock Chief Scientific Officer Conducts Multiple Sales Throughout January 2026 The Chief Scientific Officer of Scholar Rock Holding Corp has made multiple filings regarding disposals in January 2026, but this should not alarm investors.
3 Questions Investors Should Answer Before Buying Beyond Meat Stock Beyond Meat was a market darling when it first went public, but you'll want to tread cautiously if you are looking to buy it today.
Large Biotech Fund Sells Shares of Cogent Biosciences for Over $120M A large biotech fund that's an insider at Cogent Biosciences recently sold millions of shares amid the company's best annual performance ever in 2025.
Should You Buy Nio Stock While It's Below $5 a Share? Nio is an innovative auto company operating in the world's largest auto market, but I'm still bearish on it.
Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500k The Chief Scientific Officer of this biopharmaceutical company sold 20,000 shares in mid-January 2026, amid the company's stock rising 71% throughout the month.
Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes The chief medical officer at one of the top pharmaceutical companies sold nearly 10,000 shares in late January 2026, but the reason was for something very simple.
1 Underrated Reason Netflix's Growth Story Isn't Over The streaming giant's stock is trading at much lower levels than it was a year ago.
Amylyx Pharmaceuticals Co-Chief Executive Sells AMLX 138K Shares for $1.9 Million A Co-CEO of a leading neurotherapeutics developer reported significant insider selling amid a year of standout stock performance. But the sale is not what it seems.
4 Ways to Set Your 401(k) Up for Success in 2026 With the right strategy, you can grow your savings nicely this year.
Investment Firm Bouvel Raised Its Stake in This ETF by $8 Million. Is It a Buy? This actively managed fixed income ETF targets diversified bond exposure and reported a 5.09% annualized yield in its latest filing.
Harmony Biosciences' CFO Sells All of His Insider Shares, Worth $752,800 This bioscience company has had promising financials, yet one of its top executives exited his entire direct equity ownership in mid-January 2026.
Harmony Biosciences' CFO Sells All of Her Insider Shares, Worth $752,800 This bioscience company has had promising financials, yet one of its top executives exited her entire direct equity ownership in mid-January 2026.
